{"type":"trials","record":{"id":41483,"source_id":"clinicaltrials-gov","external_id":"NCT07215390","title":"A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio","brief_summary":"A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Apellis Pharmaceuticals, Inc.","enrollment":240,"countries":["United States"],"start_date":"2025-06-23","completion_date":"2027-11-01","last_update_date":"2026-06-24","source_url":"https://clinicaltrials.gov/study/NCT07215390","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":"Group 3 (placebo)","organization":"Apellis Pharmaceuticals, Inc.","interventions":["APL-3007, pegcetacoplan (APL-2)","Placebo, Syfovre"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the stu…","CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye — At month 12","Safety & tolerability based on adverse event (AE) reporting — At month 12","Safety as assessed by Best Corrected Visual Acuity (BCVA) — At Month 12","Change from baseline in Serum C3 level — At Month 12","CFB in RPE lesion area as assessed by FAF in the study eye — At month 12","CFB in the junctional zone, central 2o and 6o MP number of scotomatous points in the study eye — At month 12","CFB in the junctional zone, central 2o and 6o MP mean sensitivities in the study eye — At month 12","CFB in normal luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold Platform — At m…","CFB in low luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold platform — At mont…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy Secondary to Age-related Macular Degeneration","APL-3007, pegcetacoplan (APL-2)","Placebo, Syfovre"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07215390","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-06-23 to 2027-11-01","comparator":"Group 3 (placebo)","confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.820Z","intervention":["APL-3007, pegcetacoplan (APL-2)","Placebo, Syfovre"],"participants":240,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the stu…","CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye — At month 12","Safety & tolerability based on adverse event (AE) reporting — At month 12","Safety as assessed by Best Corrected Visual Acuity (BCVA) — At Month 12","Change from baseline in Serum C3 level — At Month 12","CFB in RPE lesion area as assessed by FAF in the study eye — At month 12","CFB in the junctional zone, central 2o and 6o MP number of scotomatous points in the study eye — At month 12","CFB in the junctional zone, central 2o and 6o MP mean sensitivities in the study eye — At month 12","CFB in normal luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold Platform — At m…","CFB in low luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold platform — At mont…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41483","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}